Maze Therapeutics (NASDAQ:MAZE) Shares Up 3.5% – Time to Buy?

Maze Therapeutics, Inc. (NASDAQ:MAZE)’s stock price shot up 3.5% on Tuesday . The company traded as high as $11.71 and last traded at $11.43. 19,890 shares were traded during mid-day trading, a decline of 93% from the average session volume of 297,836 shares. The stock had previously closed at $11.04.

Analysts Set New Price Targets

A number of equities analysts have weighed in on MAZE shares. JPMorgan Chase & Co. began coverage on Maze Therapeutics in a research note on Tuesday, February 25th. They set an “overweight” rating and a $30.00 price objective for the company. Leerink Partners began coverage on Maze Therapeutics in a research report on Tuesday, February 25th. They set an “outperform” rating and a $28.00 price target for the company. Guggenheim started coverage on Maze Therapeutics in a research report on Tuesday, February 25th. They issued a “buy” rating and a $19.00 price objective on the stock. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 25th. Finally, Leerink Partnrs upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 25th. Three investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $25.67.

Maze Therapeutics Stock Performance

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.